Related Experiment Videos
[Hypertrophic cardiomyopathy. Arrhythmia in hypertrophic cardiomyopathy]
1Departamento de Electrocardiografía y Electrofisiología Clínica, Instituto Nacional de Cardiología Ignacio Chávez, Juan Badiano No. 1, Col Sección XVI, Tlapan, CP 14080, México, D. F. México.
Insights
Hypertrophic cardiomyopathy (HCM) is a common genetic heart condition. Early diagnosis and risk stratification are key for managing sudden cardiac death risk in affected individuals.
Area of Science:
- Cardiology
- Genetics
- Medical Diagnostics
Background:
- Hypertrophic cardiomyopathy (HCM) is a prevalent genetic disorder characterized by significant heterogeneity.
- It is the leading cause of sudden cardiac death (SCD) in young individuals, particularly athletes.
Observation:
- Clinical diagnosis of HCM is supported by echocardiography, revealing abnormal septal myocardial hypertrophy.
- This hypertrophy occurs independently of other cardiac or systemic diseases like hypertension or aortic stenosis.
Findings:
- The annual mortality rate from SCD in HCM patients is approximately 1%, escalating to 3-6% in high-risk groups.
- Treatment strategies are tailored based on patient subsets, considering risks of SCD, obstructive symptoms, heart failure, and stroke.
Implications:
- Identifying high-risk individuals for sudden cardiac death is crucial.
- Automatic implantable cardioverter-defibrillators (AICDs) offer an effective treatment for patients at high risk of sudden cardiac death.
Abstract:
Hypertrophic cardiomyopathy is a relatively common genetic disorder with heterogeneity in mutations, forms of presentation, prognosis and treatment strategies. Hypertrophic cardiomyopathy is recognized as the most common cause of sudden cardiac death that occurs in young people, including athletes. The clinical diagnosis is complemented with the ecocardiographic study, in which an abnormal myocardial hypertrophy of the septum can be observed in the absence of a cardiac or systemic disease (arterial systemic hypertension, aortic stenosis). The annual sudden mortality rate is 1% and, in selected populations, it ranges between 3 and 6%. The therapeutic strategies depend on the different subsets of patients according to the morbidity and mortality, sudden cardiac death, obstructive symptoms, heart failure or atrial fibrillation and stroke. High risk patients for sudden death may effectively be treated with the automatic implantable cardioverter-defibrillator.